A Phase I trial to test the safety of a novel drug for cancer, known as AZD5363, has started recruiting at The Royal Marsden NHS Foundation Trust, London and the Christie Hospital NHS Trust in Manchester.
The purpose of this Phase I study is to investigate the safety and tolerability of a new drug AZD5363 in patients with advanced cancer, including pancreatic cancer. AZD5363 is a novel drug which blocks an enzyme, Protein Kinanse B (PKB) that is involved in cancer development and in tumours becoming resistant to some key anti-cancer drugs. The study will also look at how the body handles the drug and identify a dose schedule. The study is suitable for patients with advanced solid tumours.
For more information visit http://www.icr.ac.uk/press/press_archiv ... 9319.shtml
This forum contains news that Pancreatic Cancer UK and forum users have shared over the years.
1 post • Page 1 of 1